Officials work on their terminals inside a "Green War Room" focused on tracking air pollution, at the Secretariat Building, in New Delhi, India, October 16, 2020. Picture taken October 16, 2020. REUTERS/Anushree Fadnavis

European Council President Charles Michel reports on last week's European summit during a plenary session at the European Parliament in Brussels, Belgium 21 October 2020. The speech mainly focused on Brexit. Olivier Hoslet/Pool via REUTERS

Tracey, who volunteers for the animal rescue agency, Wildlife Information, Rescue and Education Service, also knows as WIRES, cares for twin koala joeys, who have been diagnosed as being underweight, and their mother named Gladys, who were rescued from an area where urban development is encroaching on koala habitat, at a rehabilitation enclosure next to her home, in Wedderburn, Australia, September 11, 2020. Koala conservationists are focusing more than ever on the city as population growth in metropolises like Sydney - home to a fifth of Australia's 25 million population - drives demand to clear forests and make way for homes. Traffic safety signs normally associated with tight corners and speed bumps now show the risk of koalas crossing the road in developed suburbs. "We do need housing to live in but there needs to be a balance and there needs to be a balance to ensure that these species survive," said Tracey. REUTERS/Loren Elliott SEARCH "KOALAS ELLIOTT" FOR THIS STORY. SEARCH "WIDER IMAGE" FOR ALL STORIES

A police officer stands on an abandoned water park inside the Bosque de Chapultepec as part of the project where Mexican artist, Gabriel Orozco will design, focusing on the sprawling urban park's ecological restoration and social interconnectedness, in Mexico City, Mexico October 5, 2020. Picture taken October 5, 2020.REUTERS/Carlos Jasso

The remains of an abandoned dolphin show center, are seen inside the Bosque de Chapultepec as part of the project where Mexican artist, Gabriel Orozco will design, focusing on the sprawling urban park's ecological restoration and social interconnectedness, in Mexico City, Mexico October 5, 2020. Picture taken October 5, 2020.REUTERS/Carlos Jasso

The remains of an abandoned dolphin show center, are seen inside the Bosque de Chapultepec as part of the project where Mexican artist, Gabriel Orozco will design, focusing on the sprawling urban park's ecological restoration and social interconnectedness, in Mexico City, Mexico October 5, 2020. Picture taken October 5, 2020.REUTERS/Carlos Jasso

Urban graffiti on the remains of an abandoned dolphin show center, are seen inside the Bosque de Chapultepec as part of the project were Mexican Artist, Gabriel Orozco will design, focusing on the sprawling urban park's ecological restoration and social interconnectedness, in Mexico City, Mexico October 5, 2020. Picture taken October 5, 2020.REUTERS/Carlos Jasso

An aerial view taken with a drone shows an abandoned water park inside the Bosque de Chapultepec as part of the project where Mexican artist, Gabriel Orozco will design, focusing on the sprawling urban park's ecological restoration and social interconnectedness, in Mexico City, Mexico October 5, 2020. Picture taken October 5, 2020.REUTERS/Carlos Jasso

Urban graffiti on the remains of an abandoned dolphin show center, are seen inside the Bosque de Chapultepec as part of the project where Mexican artist, Gabriel Orozco will design, focusing on the sprawling urban park's ecological restoration and social interconnectedness, in Mexico City, Mexico October 5, 2020. Picture taken October 5, 2020.REUTERS/Carlos Jasso

An aerial view taken with a drone shows the remains of an abandoned water park inside the Bosque de Chapultepec as part of the project where Mexican artist, Gabriel Orozco will design, focusing on the sprawling urban park's ecological restoration and social interconnectedness, in Mexico City, Mexico October 5, 2020. Picture taken October 5, 2020.REUTERS/Carlos Jasso

The remains of an abandoned water park are seen inside the Bosque de Chapultepec as part of the project where Mexican artist, Gabriel Orozco will design, focusing on the sprawling urban park's ecological restoration and social interconnectedness, in Mexico City, Mexico October 5, 2020. Picture taken October 5, 2020.REUTERS/Carlos Jasso

An aerial view taken with a drone shows an abandoned water park inside the Bosque de Chapultepec as part of the project where Mexican artist, Gabriel Orozco will design, focusing on the sprawling urban park's ecological restoration and social interconnectedness, in Mexico City, Mexico October 5, 2020. Picture taken October 5, 2020.REUTERS/Carlos Jasso

An aerial view taken with a drone shows an abandoned water park inside the Bosque de Chapultepec as part of the project where Mexican artist, Gabriel Orozco will design, focusing on the sprawling urban park's ecological restoration and social interconnectedness, in Mexico City, Mexico October 5, 2020. Picture taken October 5, 2020.REUTERS/Carlos Jasso

Representative Tom Rice (R-SC) speaks during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Representative Michael Cloud (R-TX) displays a chart on prescripction drugs during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Ralph Norman (R-S.C.) is seen during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Kweisi Mfume (D-Md.) speaks during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Ralph Norman (R-SC) uses a mobile phone as Representative Michael Cloud (R-TX) speaks during to a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Representative Michael Cloud (R-TX) speaks during to a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Representative Peter Welch (D-Vt.) attends a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Representative Peter Welch (D-Vt.) talk to Representative Gerald Connolly (D-Va.) during to a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Gerald Connolly (D-Va.) delivers a statement during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Jody Hice (R-Ga.) displays a chart during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Gerald Connolly (D-Va.) displays a chart on European drug prices during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Bristol-Myers Squibb CEO Giovanni Caforio testifies by video conference during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Virginia Foxx (R-N.C.) questions Bristol-Myers Squibb CEO Giovanni Caforio by video conference during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Virginia Foxx (R-N.C.) questions Bristol-Myers Squibb CEO Giovanni Caforio by video conference during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Peter Welch (D-Vt.) speaks during to a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Representative Tom Rice (R-SC) speaks with Representative Jim Jordan (R-OH) during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Representative Jim Jordan (R-OH) speaks with Ranking Member James Comer (R-KY) during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Representative Jim Jordan (R-OH) speaks with Representative Ralph Norman (R-SC) during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Chairwoman Carolyn Maloney (D-NY) holds up a document as she questions witnesses during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Teva Pharmaceuticals CEO Kare Schultz testifies by video conference during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Celgene Corporation former CEO Mark Alles testifies by video conference during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Bristol-Myers Squibb CEO Giovanni Caforio testifies by video conference during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Bristol-Myers Squibb CEO Giovanni Caforio, Teva Pharmaceuticals CEO Kare Schultz, and Celgene Corporation former CEO Mark Alles are sworn in prior to testifying by video conference during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Bristol-Myers Squibb CEO Giovanni Caforio, Teva Pharmaceuticals CEO Kare Schultz, and Celgene Corporation former CEO Mark Alles are sworn in prior to testifying by video conference during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Teva Pharmaceuticals CEO Kare Schultz testifies by video conference during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Bristol-Myers Squibb CEO Giovanni Caforio testifies by video conference during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Celgene Corporation former CEO Mark Alles testifies by video conference during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Teva Pharmaceuticals CEO Kare Schultz testifies by video conference during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Ranking Member James Comer (R-KY) bumps elbows with Chairwoman Carolyn Maloney (D-NY) prior to a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative James Comer (R-Ky.) speaks to Representative Gary Palmer (R-Ala.) prior to a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Peter Welch (D-Vt.) is seen during to a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Thomas Massie (R-Ky.) arrives to attend a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Peter Welch (D-Vt.) is seen prior to a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Virginia Foxx (R-N.C.) speaks to Chairwoman Carolyn Maloney (D-NY) prior to a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Ranking Member James Comer (R-KY) delivers his opening statement during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Chairwoman Carolyn Maloney (D-NY) arrives to attend a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Chairwoman Carolyn Maloney (D-NY) delivers an opening statement during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Chairwoman Carolyn Maloney (D-NY) delivers an opening statement during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Chairwoman Carolyn Maloney (D-NY) delivers an opening statement during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Greg Nash/Pool via REUTERS

Representative Tom Rice (R-SC) delivers his opening statement during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Ranking Member James Comer (R-KY) delivers his opening statement during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Ranking Member James Comer (R-KY) prepares to deliver his opening statement during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Chairwoman Carolyn Maloney (D-NY) delivers an opening statement during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Chairwoman Carolyn Maloney (D-NY) delivers an opening statement during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Chairwoman Carolyn Maloney (D-NY) delivers an opening statement during a hearing before the US House of Representatives Committee on Oversight and Reform focused on the cost of prescription drugs, in the U.S. Capitol, in Washington, U.S., September 30, 2020 Alex Edelman/Pool via REUTERS

Senator Doug Jones (D-AL) asks a question during a U.S. Senate Senate Health, Education, Labor, and Pensions Committee Hearing to examine COVID-19, focusing on an update on the federal response at the U.S. Capitol in Washington, D.C., U.S., September 23, 2020. Alex Edelman/Pool via REUTERS

Anthony Fauci, MD, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, listens to questioning as he testifies during a U.S. Senate Senate Health, Education, Labor, and Pensions Committee Hearing to examine COVID-19, focusing on an update on the federal response at the U.S. Capitol in Washington, D.C., U.S., September 23, 2020. Alex Edelman/Pool via REUTERS